Bank of Montreal Can Acquires 21,132 Shares of IDEXX Laboratories, Inc. $IDXX

Bank of Montreal Can raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 21.1% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 121,101 shares of the company’s stock after buying an additional 21,132 shares during the period. Bank of Montreal Can’s holdings in IDEXX Laboratories were worth $64,951,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of IDXX. Opal Wealth Advisors LLC bought a new position in IDEXX Laboratories in the 2nd quarter valued at $29,000. Migdal Insurance & Financial Holdings Ltd. grew its position in IDEXX Laboratories by 55.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company’s stock valued at $35,000 after acquiring an additional 30 shares during the last quarter. Ameritas Advisory Services LLC bought a new position in IDEXX Laboratories in the 2nd quarter valued at $36,000. WPG Advisers LLC bought a new position in IDEXX Laboratories in the 1st quarter valued at $37,000. Finally, Bank of Jackson Hole Trust grew its position in IDEXX Laboratories by 328.6% in the 1st quarter. Bank of Jackson Hole Trust now owns 90 shares of the company’s stock valued at $39,000 after acquiring an additional 69 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

IDXX opened at $722.12 on Wednesday. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $735.00. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. The business’s fifty day simple moving average is $641.13 and its 200-day simple moving average is $574.15. The company has a market capitalization of $57.77 billion, a price-to-earnings ratio of 60.13, a PEG ratio of 4.06 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, November 3rd. The company reported $3.40 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.26. The firm had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm’s quarterly revenue was up 13.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.80 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have commented on IDXX. Jefferies Financial Group reaffirmed a “buy” rating and issued a $830.00 price objective on shares of IDEXX Laboratories in a research report on Tuesday. Stifel Nicolaus set a $775.00 price target on IDEXX Laboratories in a research report on Monday. BTIG Research increased their price target on IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a research report on Tuesday. Morgan Stanley increased their price target on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research report on Tuesday. Finally, Wall Street Zen downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Sunday, September 28th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $730.50.

Insider Buying and Selling

In related news, EVP Sharon E. Underberg sold 5,450 shares of the company’s stock in a transaction on Friday, August 8th. The stock was sold at an average price of $651.60, for a total transaction of $3,551,220.00. Following the completion of the sale, the executive vice president directly owned 6,156 shares in the company, valued at $4,011,249.60. This represents a 46.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Michael G. Erickson sold 406 shares of the company’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $649.96, for a total value of $263,883.76. Following the sale, the executive vice president owned 11,287 shares of the company’s stock, valued at $7,336,098.52. This trade represents a 3.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 9,243 shares of company stock valued at $6,018,650. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.